Overview
Cartilage-hair hypoplasia (CHH), also known as metaphyseal chondrodysplasia, McKusick type, is a rare autosomal recessive skeletal dysplasia caused by mutations in the RMRP gene, which encodes the RNA component of the mitochondrial RNA-processing endoribonuclease complex. The condition was first described in the Old Order Amish population but occurs worldwide. CHH is characterized by short-limbed short stature (dwarfism) that is evident at birth, with disproportionately short limbs relative to the trunk. The skeletal abnormalities result from defective cartilage growth, particularly at the metaphyses of long bones. Fine, sparse, light-colored hair with reduced diameter is a hallmark feature, though hair findings can vary in severity. Beyond the skeletal and hair manifestations, CHH affects multiple body systems. A significant proportion of patients have immune deficiency ranging from mild to severe combined immunodeficiency, which increases susceptibility to infections, particularly viral infections such as varicella. Affected individuals also have an increased risk of malignancies, especially non-Hodgkin lymphoma and other cancers, as well as basal cell carcinoma. Additional features may include macrocytic anemia or other hematologic abnormalities, Hirschsprung disease, and impaired spermatogenesis in males. Joint hypermobility, particularly of the hands, and ligamentous laxity are common. Treatment of CHH is largely supportive and symptom-directed. Growth hormone therapy has been used with limited benefit. For patients with severe combined immunodeficiency, hematopoietic stem cell transplantation (HSCT) may be considered and can correct the immunological defects. Immunoglobulin replacement therapy may be used for antibody deficiency. Regular monitoring for malignancies and infections is essential. Orthopedic interventions may be needed for skeletal complications such as leg bowing. Prognosis varies widely depending on the severity of immune dysfunction, with some patients having a near-normal lifespan while others face life-threatening complications from infections or malignancy.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Cartilage-hair hypoplasia.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Cartilage-hair hypoplasia at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Cartilage-hair hypoplasia.
Community
No community posts yet. Be the first to share your experience with Cartilage-hair hypoplasia.
Start the conversation →Latest news about Cartilage-hair hypoplasia
No recent news articles for Cartilage-hair hypoplasia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cartilage-hair hypoplasia
What is Cartilage-hair hypoplasia?
Cartilage-hair hypoplasia (CHH), also known as metaphyseal chondrodysplasia, McKusick type, is a rare autosomal recessive skeletal dysplasia caused by mutations in the RMRP gene, which encodes the RNA component of the mitochondrial RNA-processing endoribonuclease complex. The condition was first described in the Old Order Amish population but occurs worldwide. CHH is characterized by short-limbed short stature (dwarfism) that is evident at birth, with disproportionately short limbs relative to the trunk. The skeletal abnormalities result from defective cartilage growth, particularly at the met
How is Cartilage-hair hypoplasia inherited?
Cartilage-hair hypoplasia follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Cartilage-hair hypoplasia typically begin?
Typical onset of Cartilage-hair hypoplasia is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Cartilage-hair hypoplasia?
16 specialists and care centers treating Cartilage-hair hypoplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.